Clinical Research Directory
Browse clinical research sites, groups, and studies.
Duration of Androgen Receptor Pathway Inhibitor and ADT With Metastasis Directed Therapy in Oligometastatic Cancer of the Prostate (DIRECT)
Sponsor: University Health Network, Toronto
Summary
This is a multi-centre, investigator-initiated, two-arm, randomized trial to investigate the addition on androgen receptor pathway inhibitor to standard of care radiation and hormone therapy improve quality of life. Participants will either receive standard of care radiation and hormone (ADT) therapy (Arm 1) or standard of care radiation and hormone (ADT) therapy plus oral abiraterone for 8-9 months (Arm 3). Participants will be routinely follow-up in clinic or remotely for up to 5 years.
Official title: Duration of Androgen Receptor Pathway Inhibitor and ADT With Metastasis Directed Therapy in Oligometastatic Cancer of the Prostate
Key Details
Gender
MALE
Age Range
18 Years - 100 Years
Study Type
INTERVENTIONAL
Enrollment
132
Start Date
2023-05-24
Completion Date
2026-03
Last Updated
2024-11-25
Healthy Volunteers
No
Conditions
Interventions
Enzalutamide
Second-generation androgen pathway inhibitor (ARAT), oral tablet
Standard of Care SBRT and ADT
Standard of care stereotactic body radiation therapy (SBRT) and androgen deprivation therapy (ADT)
Locations (2)
Princess Margaret Cancer Center
Toronto, Ontario, Canada
Sunnybrook Research Institute
Toronto, Ontartio, Canada